Akston Biosciences Corporation
100 Cummings Center, Suite 454C
Beverly
Massachusetts
01915
United States
Website: https://www.akstonbio.com/
15 articles about Akston Biosciences Corporation
-
Akston Biosciences Receives 2023 Most Innovative Award at Animal Health Summit
8/31/2023
Akston Biosciences Corporation, which invents, develops and manufactures breakthrough protein therapeutics for Companion Animal Health, received the 2023 Innovation Award at the just-concluded Animal Health Summit in Kansas City, MO.
-
Akston Biosciences CEO to Present at the 2023 Animal Health Summit in Kansas City
8/28/2023
Akston Biosciences Corporation, which invents, develops and manufactures breakthrough protein therapeutics for Companion Animal Health, announced that President & CEO Todd Zion, Ph.D., will present at the 2023 Animal Health Summit in Kansas City, MO on August 28, 2023.
-
While it was a relatively quiet week for clinical trial announcements overall, BioSpace takes a look at some of the more intriguing ones.
-
Biolexis and Akston Biosciences Announce Encouraging Top-Line Results from Phase II/III Trial of their Thermostable 2nd Gen COVID-19 Vaccine
6/24/2022
Biolexis and Akston Biosciences Announce Encouraging Top-Line Results from Phase II/III Trial of their Thermostable 2nd Gen COVID-19 Vaccine.
-
Akston Biosciences Doses First Participants in Phase II Clinical Trial for Shelf-Stable COVID-19 Booster
5/12/2022
Akston Biosciences Corporation, a developer of new classes of biologic therapeutics, announced today it dosed the first set of volunteers in an open-label study of AKS-452, its protein subunit COVID-19 vaccine, as a booster.
-
Akston Biosciences CEO to Present at the World Vaccine Congress - Apr 12, 2022
4/12/2022
Akston Biosciences Corporation, a developer of new classes of biologics, announced that its president and CEO, Todd Zion, Ph.D., has been invited to present at this year’s World Vaccine Congress.
-
Akston Biosciences Receives Regulatory Approval for Phase II Clinical Trial for Shelf-Stable COVID-19 Vaccine Booster
3/31/2022
Akston Biosciences Corporation, a developer of new classes of biologic therapeutics, announced today it received regulatory approval in the Netherlands to conduct an open-label study of AKS-452, its protein subunit COVID-19 vaccine, as a booster.
-
Akston Biosciences and Biolexis Collaborate to Launch a Room Temperature Stable 2nd Generation COVID-19 Vaccine in 130+ Countries
3/17/2022
Akston Biosciences and Biolexis Collaborate to Launch a Room Temperature Stable 2nd Generation COVID-19 Vaccine in 130+ Countries.
-
Akston Biosciences Announces Publication in Vaccine of Positive Data for a Room Temperature Protein Subunit COVID-19 Vaccine
2/8/2022
Akston Biosciences Corporation, a developer of new classes of biologic therapeutics, announced publication of positive results from a 60-subject, open-label, Phase I trial of AKS-452, its shelf stable protein subunit COVID-19 vaccine candidate.
-
Akston Biosciences Announces Positive Top-Line Data From Phase II Study of COVID-19 Vaccine in the Netherlands
12/22/2021
Akston Biosciences, Inc. a developer of new classes of biologic therapeutics, announced positive data from the Phase II clinical trial of its second-generation SARS-CoV2 vaccine candidate, AKS-452.
-
Akston Biosciences Doses First Subjects in Phase II Clinical Trial in India of Second-Generation COVID-19 Vaccine
11/20/2021
Akston Biosciences Corporation, a developer of new classes of biologic therapeutics, announced that the first of 100 subjects were dosed in an open-label bridging study of AKS-452, its protein subunit COVID-19 vaccine candidate, in India.
-
Akston Biosciences Announces Commercial Supply Agreement of Seppic’s Adjuvant to Formulate Akston Shelf-Stable COVID-19 Vaccine at Global Scale
7/21/2021
Akston Biosciences Corporation today announced a commercial agreement with Seppic S.A., a supplier of specialty healthcare ingredients, for the supply of adjuvant for use in Akston’s COVID-19 Fc fusion protein vaccine candidate, AKS-452.
-
Akston Biosciences Announces Positive Phase I Data for Second-Generation COVID-19 Vaccine Candidate
7/8/2021
Today, Akston Biosciences Corporation , a developer of new classes of biologic therapeutics announced positive results from a 60-subject, open-label, Phase I trial of AKS-452, its protein subunit, room temperature stable, COVID-19 vaccine candidate.
-
Akston Biosciences Launches Phase I/II Clinical Trial of Second-Generation COVID-19 Vaccine
4/12/2021
First subjects dosed with AKS-452, COVID-19 vaccine candidate in the Netherlands trial Vaccine is shelf-stable for 4 months at 25 degrees Celsius (77° Fahrenheit) 176 volunteers will participate in the clinical trial
-
Helmsley Charitable Trust And Akston Biosciences Announce Partnership To Advance Novel Technology To Treat Type 1 Diabetes
3/16/2017